Latest Protein kinases Stories
All cells need glucose (sugar) to produce the energy they need to survive.
While some “couch potatoes” might attribute their lack of resolve to exercise to mere laziness, researchers have discovered these people may simply be missing some vital genes.
A new study describes how hyperactivation of AMP-activated protein kinase (AMPK) promotes neurodegeneration in Huntington's disease (HD).
Biotech scientists are working on novel protein kinase inhibitors that are targeting a host of conditions ranging from atherosclerosis to neurodegenerative diseases.
Crown Bioscience, Inc. announces their partnership with Allostem Therapeutics providing discovery and pre-clinical translational oncology services for Allostemâ€™s MEK inhibitor program. CIP-137401 is the clinical candidate from a novel MEK inhibitor scaffold with Best-In-Class potential.
QUÃ‰BEC CITY, March 15 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:Â AEZS) (TSX:Â AEZ) (the "Company") today announced that its Senior Director,Â Head of Preclinical Development, Michael Teifel, Ph.D., will present preclinical results for PI3K/Erk inhibitors AEZS-129, AEZS-131, and AEZS-132, which support further evaluation as potential anticancer compounds.
JAMAICA PLAIN, Mass., March 1, 2011 /PRNewswire/ -- Paloma Pharmaceuticals, Inc. announced today updates on its age-related macular degeneration Phase I trials and oncology program.
SINGAPORE, Feb. 28, 2011 /PRNewswire/ -- S*BIO Pte Ltd today announced that its novel dual mTOR/PI3 Kinase inhibitor SB2343 demonstrated excellent pharmacokinetic/pharmacodynamic (PK/PD) properties leading to significant anti-tumor efficacy in rapamycin-sensitive and resistant xenograft models.
Prediction of over 30 million human kinase-substrate interactions now available at PhosphoNET website VANCOUVER, BC, Feb.
- An armed gangster.